Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
WINDTREE THERAPEUTICS INC /DE/ incurred convertible notes of $1,600,000 with institutional investors at 10% per annum on a 360-day basis maturing October 9, 2026.
- Instrument
- convertible notes
- Principal
- $1,600,000
- Counterparty
- institutional investors
- Rate
- 10% per annum on a 360-day basis
- Maturity
- October 9, 2026
- Event
- incurrence
Exact text from the filing
On October 9, 2025, Windtree Therapeutics, Inc. (the “Company”) issued to institutional investors (collectively, “Holders” and each a “Holder”) an aggregate principal amount of $1,600,000 in senior convertible promissory notes due 2026 (the “Commitment Notes”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.7
WINDTREE THERAPEUTICS INC /DE/ issued 80% of the cash purchase price paid per share, unit or other security denomination of convertible note to the other investors in such transaction for cash purchase price.
- Security
- convertible note
- Shares
- 80% of the cash purchase price paid per share, unit or other security denomination
- Purchaser
- the other investors in such transaction
- Consideration
- cash purchase price
Exact text from the filing
Item 3.02 Unregistered Sales of Equity Securities. The disclosure set forth under Item 3.01 relating to the Commitment Notes is hereby incorporated into this Item 3.02 by reference. The foregoing description of the Commitment Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Commitment Notes, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company issued the Commitment Notes in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder.
View on SEC.gov